A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy

被引:11
|
作者
Adhikarla, Vikram [1 ]
Awuah, Dennis [2 ]
Brummer, Alexander B. [1 ]
Caserta, Enrico [3 ]
Krishnan, Amrita [2 ]
Pichiorri, Flavia [3 ]
Minnix, Megan [4 ]
Shively, John E. [4 ]
Wong, Jeffrey Y. C. [5 ]
Wang, Xiuli [2 ]
Rockne, Russell C. [1 ]
机构
[1] City Hope Natl Med Ctr, Div Math Oncol, Dept Computat & Quantitat Med, Beckman Res Inst,Natl Med Ctr, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Dept Mol Imaging & Therapy, Natl Med Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Dept Radiat Oncol, Natl Med Ctr, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
CAR-T; targeted radionuclide therapy; TRT; mathematical model; multiple myeloma; immunotherapy; daratumumab; CS1; combination therapy; alpha particle therapy; actinium-225; IMMUNOTHERAPY;
D O I
10.3390/cancers13205171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results, an example being chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies. Moreover, TRT and CAR-T therapies possess unique features that require special consideration when determining how to dose as well as the timing and sequence of combination treatments including the distribution of the TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate the additive or synergistic effects of combination therapies and warrant a mathematical treatment that includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here, we combine two previously published mathematical models to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell-based therapies in a multiple myeloma setting. We find that, for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR-T therapies.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer
    Yan, Wenying
    Hu, Hongmei
    Tang, Biao
    ONCOTARGETS AND THERAPY, 2019, 12 : 8015 - 8022
  • [32] Prospects of chimeric antigen receptor T cell therapy in ovarian cancer
    Vishal Jindal
    Ena Arora
    Sorab Gupta
    Amos Lal
    Muhammad Masab
    Rashmika Potdar
    Medical Oncology, 2018, 35
  • [33] Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists
    Nusbaum, Kelsey B.
    Dulmage, Brittany
    Choi, Jennifer N.
    Jaglowski, Samantha M.
    Korman, Abraham M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : 597 - 604
  • [34] Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
    Jindal, Vishal
    Khoury, John
    Gupta, Ruby
    Jaiyesimi, Ishmael
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (05): : 371 - 377
  • [35] The potential of chimeric antigen receptor -T cell therapy for endocrine cancer
    Ruonan Yu
    Xiaoyu Ji
    Ping Zhang
    Hao Zhang
    Huiling Qu
    Wenwu Dong
    World Journal of Surgical Oncology, 23 (1)
  • [36] Chimeric antigen receptor T-cell therapy for breast cancer
    Gharghani, Mighmig Simonian
    Simonian, Miganoosh
    Bakhtiari, Faezeh
    Ghaffari, Mozhan Haji
    Fazli, Ghazaleh
    Bayat, Ali Ahmad
    Negahdari, Babak
    FUTURE ONCOLOGY, 2021, 17 (22) : 2961 - 2979
  • [37] Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
    Wala, Jeremiah A.
    Hanna, Glenn J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1149 - 1168
  • [38] Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
    Sur, Daniel
    Havasi, Andrei
    Cainap, Calin
    Samasca, Gabriel
    Burz, Claudia
    Balacescu, Ovidiu
    Lupan, Iulia
    Deleanu, Diana
    Irimie, Alexandru
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
  • [39] Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist
    Maus, Marcela V.
    Levine, Bruce L.
    ONCOLOGIST, 2016, 21 (05) : 608 - 617
  • [40] Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy
    Xue, Tongqing
    Zhao, Xiang
    Zhao, Kun
    Lu, Yan
    Yao, Juan
    Ji, Xianguo
    CURRENT PROBLEMS IN CANCER, 2022, 46 (01)